M&A Deal Summary |
|
|---|---|
| Date | 2020-04-28 |
| Target | Tocagen - Replicating Gene Therapy Platform and Related Assets |
| Sector | Life Science |
| Buyer(s) | Denovo Biopharma |
| Sellers(s) | Tocagen |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
Denovo Biopharma LLC is a biopharmaceutical company that applies novel biomarker approaches to re-evaluate medicines that have failed in broad patient populations. The company seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. Denovo then designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo Biopharma was founded in 2011 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Life Science |
| Revenue | 18M USD (2018) |
Tocagen is a fully integrated global biotech company that develops first-in-class, broadly applicable, product candidates, that are designed to activate a patient’s immune system against their own cancer from within. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. Tocagen was formed in 2007 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |
